In the presence of CML, however, a co-injection of apoA-I (1.4 ng) alone or CIGB-258 alone (143 pg) resulted in a higher survivability of around 37 ± 5% and 33 ± 1%, respectively, suggesting that either apoA-I or CIGB-258 possessed adequate anti-inflammatory activity to neutralize the CML toxicity. This evidence concerns the gene APOA1 and chronic myelogenous leukemia, BCR-ABL1 positive.